Latest Financial Position News

Javelin Minerals has completed Phase 1 drilling at its Coogee Gold Project with assay results pending, while finalizing the acquisition of the Eureka Gold Project and preparing for further drilling in early 2025.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.

Australia United Mining Limited reported steady progress in its New South Wales and Queensland gold projects during the December 2024 quarter, including production from the Ropewalk mine and promising trenching results. Despite limited cash reserves, the company plans to sustain operations with ongoing financial support.

Investigator Resources Limited has postponed the Definitive Feasibility Study (DFS) for its Paris Silver Project to mid-2025, citing rising costs and the need for further optimisation. Meanwhile, exploration drilling continues and asset sales bolster the company’s cash position to $2.7 million.

Prospech Limited has reported a significant milestone with a JORC-compliant Inferred Mineral Resource Estimate of 7.1 million tonnes at 1.08% TREO for its Korsnäs REE project in Finland, alongside successful EU grant funding and a rights issue raising nearly $786,000.

Santana Minerals has reported a robust Pre-feasibility Study for its Bendigo-Ophir Gold Project, lifting the after-tax NPV to A$1.2 billion and IRR to 76%, as it progresses detailed engineering and fast-track permitting in New Zealand.

Horizon Gold advances its Gum Creek Gold Project with ongoing diamond drilling and a major upcoming RC drilling campaign aimed at upgrading its 2.14 million ounce gold resource. The company also strengthens its balance sheet following a strategic share sale.

Fortescue Metals Group has delivered its highest ever half-year iron ore shipments of 97.1 million tonnes, alongside a notable 10% reduction in hematite production costs, underscoring operational strength and advancing decarbonisation efforts.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Powerhouse Ventures Limited reports a robust quarterly performance with a notable uplift in net tangible assets to 10.4 cents per share, driven by strategic acquisitions and active investment management.

Core Lithium reports steady progress on its Finniss lithium project restart study, backed by a solid $50 million cash position and promising lithium and gold drilling results.

Netwealth Group Limited has reported a record $4.5 billion in net inflows for the December 2024 quarter, marking a 69.8% increase year-on-year and driving its funds under administration past $100 billion.